title: Severe cytomegalovirus enterocolitis after standard chemotherapy for non-Hodgkin's lymphoma.
abstract: Reports of cytomegalovirus (CMV) colitis mainly concern patients with immunocompromisation resulting from, among others, HIV infection, allogeneic bone marrow transplantation and solid organ transplantation. CMV colitis rarely occurs during standard chemotherapy for non-Hodgkin's lymphoma (NHL). An unusual case of CMV enterocolitis in a 62-year-old patient is reported. After a first course of salvage chemotherapy for NHL, diffuse erosions and sloughing mucosa were seen throughout the large bowel. The final diagnosis was based on histological findings. Although ganciclovir and foscarnet are effective for CMV viremia, their use in the treatment of severe diarrhea in our patient did not result in improvement for one week, whereas concomitant use of octreotide led to rapid improvement. Octreotide may therefore be an effective agent for severe colitis.
authors.affiliation: Department of Molecular Hematology and Oncology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan. nomuken@koto.kpu-m.ac.jp
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nomura
authors.forename: Yuri
authors.initials: Y
authors.lastname: Kamitsuji
authors.forename: Eri
authors.initials: E
authors.lastname: Kono
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Naohisa
authors.initials: N
authors.lastname: Yoshida
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Konishi
authors.forename: Shigeo
authors.initials: S
authors.lastname: Horiike
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okanoue
authors.forename: Masafumi
authors.initials: M
authors.lastname: Taniwaki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects; D003586:Cytomegalovirus Infections / Q000139:chemically induced* / Q000188:drug therapy; D003907:Dexamethasone / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D004760:Enterocolitis / Q000139:chemically induced* / Q000188:drug therapy / Q000821:virology; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects
chemical_list: D005765:Gastrointestinal Agents; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D015282:Octreotide